Zhi-Ming Shao (Zhiming Shao, Zhimin Shao)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 59

Top Venues

Cancer research

Cancer biology & medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cell research

Fudan University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Fudan University

China

PHD :: Surgery

Publications

Xiao-Hong Ding, Yi Xiao, Fenfang Chen, Cheng-Lin Liu, Tong Fu, Zhi-Ming Shao, Yi-Zhou Jiang
The HLA-I landscape confers prognosis and antitumor immunity in breast cancer. Briefings in bioinformatics 25 (3) (2024)
Min-Ying Huang, Shu-Yuan Hu, Jia Dong, Ling Deng, Lisa Andriani, Xiao-Yan Ma, Yin-Ling Zhang, Fang-Lin Zhang, Zhi-Ming Shao, Da-Qiang Li
The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer. Cancer research 84 (16) (2024)
Li-Ping Ge, Xi Jin, Ding Ma, Zi-Yu Wang, Cheng-Lin Liu, Chao-Zheng Zhou, Shen Zhao, Tian-Jian Yu, Xi-Yu Liu, Gen-Hong Di, Zhi-Ming Shao, Yi-Zhou Jiang
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell research 34 (1) (2024)
Yu-Wei Li, Lei-Jie Dai, Xiang-Rong Wu, Shen Zhao, Yu-Zheng Xu, Xi Jin, Yi Xiao, Ying Wang, Cai-Jin Lin, Yi-Fan Zhou, Zhi-Ming Shao, Wen-Tao Yang, Ming Li, Hong Lv, Siyuan Chen, Anita Grigoriadis, Yi-Zhou Jiang, Ding Ma, Zhi-Ming Shao
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies. Cancer research (2024)
Min-Ying Huang, Shu-Yuan Hu, Jia Dong, Ling Deng, Lisa Andriani, Xiao-Yan Ma, Yin-Ling Zhang, Fang-Lin Zhang, Zhi-Ming Shao, Da-Qiang Li
The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer. Cancer research (2024)
Jia-Han Ding, Yi Xiao, Fan Yang, Xiao-Qing Song, Ying Xu, Xiao-Hong Ding, Rui Ding, Zhi-Ming Shao, Gen-Hong Di, Yi-Zhou Jiang
Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer. Science translational medicine 16 (728) (2024)
Liang Huang, Da Pang, Hongjian Yang, Wei Li, Shusen Wang, Shude Cui, Ning Liao, Yongsheng Wang, Chuan Wang, Yuan-Ching Chang, Hwei-Chung Wang, Seok Yun Kang, Jae Hong Seo, Kunwei Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Haiyan Wang, François Lamour, Grace Song, Michelle Curran, Chunzhe Duan, Sanne Lysbet de Haas, Eleonora Restuccia, Zhi-Ming Shao
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nature communications 15 (1) (2024)
Jia-Han Ding, Yi Xiao, Fan Yang, Xiao-Qing Song, Ying Xu, Xiao-Hong Ding, Rui Ding, Zhi-Ming Shao, Gen-Hong Di, Yi-Zhou Jiang
Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer. Science translational medicine 16 (728) (2024)
Yi-Zhou Jiang, Ding Ma, Xi Jin, Yi Xiao, Ying Yu, Jinxiu Shi, Yi-Fan Zhou, Tong Fu, Cai-Jin Lin, Lei-Jie Dai, Cheng-Lin Liu, Shen Zhao, Guan-Hua Su, Wanwan Hou, Ya-Qing Liu, Qing-Wang Chen, Jingcheng Yang, Naixin Zhang, Wen-Juan Zhang, Wei Liu, Weigang Ge, Wen-Tao Yang, Chao You, Yajia Gu, Virginia Kaklamani, François Bertucci, Claire Verschraegen, Anneleen Daemen, Nakul M Shah, Ting Wang, Tiannan Guo, Le-Ming Shi, Charles M Perou, Yuanting Zheng, Wei Huang, Zhi-Ming Shao
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nature cancer 5 (4) (2024)
Liang Huang, Da Pang, Hongjian Yang, Wei Li, Shusen Wang, Shude Cui, Ning Liao, Yongsheng Wang, Chuan Wang, Yuan-Ching Chang, Hwei-Chung Wang, Seok Yun Kang, Jae Hong Seo, Kunwei Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Haiyan Wang, François Lamour, Grace Song, Michelle Curran, Chunzhe Duan, Sanne Lysbet de Haas, Eleonora Restuccia, Zhi-Ming Shao
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nature communications 15 (1) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Jie Xia, Lixing Zhang, Xilei Peng, Juchuanli Tu, Siqin Li, Xueyan He, Fengkai Li, Jiankun Qiang, Haonan Dong, Qiaodan Deng, Cuicui Liu, Jiahui Xu, Rui Zhang, Quentin Liu, Guo-Hong Hu, Chong Liu, Yi-Zhou Jiang, Zhi-Ming Shao, Ceshi Chen, Suling Liu
IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer research 84 (14) (2024)
Li-Ping Ge, Xi Jin, Ding Ma, Zi-Yu Wang, Cheng-Lin Liu, Chao-Zheng Zhou, Shen Zhao, Tian-Jian Yu, Xi-Yu Liu, Gen-Hong Di, Zhi-Ming Shao, Yi-Zhou Jiang
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell research (2024)
Yuwei Li, Yuzheng Xu, Caijin Lin, Xi Jin, Ding Ma, Zhi-Ming Shao
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer biology & medicine 21 (5) (2024)
Xiao-Hong Ding, Yi Xiao, Fenfang Chen, Cheng-Lin Liu, Tong Fu, Zhi-Ming Shao, Yi-Zhou Jiang
The HLA-I landscape confers prognosis and antitumor immunity in breast cancer. Briefings in bioinformatics 25 (3) (2024)
Li-Ping Ge, Xi Jin, Ding Ma, Zi-Yu Wang, Cheng-Lin Liu, Chao-Zheng Zhou, Shen Zhao, Tian-Jian Yu, Xi-Yu Liu, Gen-Hong Di, Zhi-Ming Shao, Yi-Zhou Jiang
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell research 34 (1) (2024)
Chao You, Guan-Hua Su, Xu Zhang, Yi Xiao, Ren-Cheng Zheng, Shi-Yun Sun, Jia-Yin Zhou, Lu-Yi Lin, Ze-Zhou Wang, He Wang, Yan Chen, Wei-Jun Peng, Yi-Zhou Jiang, Zhi-Ming Shao, Ya-Jia Gu
Multicenter radio-multiomic analysis for predicting breast cancer outcome and unravelling imaging-biological connection. NPJ precision oncology 8 (1) (2024)
Xiao-Hong Ding, Yi Xiao, Fenfang Chen, Cheng-Lin Liu, Tong Fu, Zhi-Ming Shao, Yi-Zhou Jiang
The HLA-I landscape confers prognosis and antitumor immunity in breast cancer. Briefings in bioinformatics 25 (3) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Li-Ping Ge, Xi Jin, Ding Ma, Zi-Yu Wang, Cheng-Lin Liu, Chao-Zheng Zhou, Shen Zhao, Tian-Jian Yu, Xi-Yu Liu, Gen-Hong Di, Zhi-Ming Shao, Yi-Zhou Jiang
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell research 34 (1) (2024)
Jie Xia, Lixing Zhang, Xilei Peng, Juchuanli Tu, Siqin Li, Xueyan He, Fengkai Li, Jiankun Qiang, Haonan Dong, Qiaodan Deng, Cuicui Liu, Jiahui Xu, Rui Zhang, Quentin Liu, Guo-Hong Hu, Chong Liu, Yi-Zhou Jiang, Zhi-Ming Shao, Ceshi Chen, Suling Liu
IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer research 84 (14) (2024)
Yi-Zhou Jiang, Ding Ma, Xi Jin, Yi Xiao, Ying Yu, Jinxiu Shi, Yi-Fan Zhou, Tong Fu, Cai-Jin Lin, Lei-Jie Dai, Cheng-Lin Liu, Shen Zhao, Guan-Hua Su, Wanwan Hou, Ya-Qing Liu, Qing-Wang Chen, Jingcheng Yang, Naixin Zhang, Wen-Juan Zhang, Wei Liu, Weigang Ge, Wen-Tao Yang, Chao You, Yajia Gu, Virginia Kaklamani, François Bertucci, Claire Verschraegen, Anneleen Daemen, Nakul M Shah, Ting Wang, Tiannan Guo, Le-Ming Shi, Charles M Perou, Yuanting Zheng, Wei Huang, Zhi-Ming Shao
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nature cancer 5 (4) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Jia-Han Ding, Yi Xiao, Fan Yang, Xiao-Qing Song, Ying Xu, Xiao-Hong Ding, Rui Ding, Zhi-Ming Shao, Gen-Hong Di, Yi-Zhou Jiang
Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer. Science translational medicine 16 (728) (2024)
Xiao-Hong Ding, Yi Xiao, Fenfang Chen, Cheng-Lin Liu, Tong Fu, Zhi-Ming Shao, Yi-Zhou Jiang
The HLA-I landscape confers prognosis and antitumor immunity in breast cancer. Briefings in bioinformatics 25 (3) (2024)
Jie Xia, Lixing Zhang, Xilei Peng, Juchuanli Tu, Siqin Li, Xueyan He, Fengkai Li, Jiankun Qiang, Haonan Dong, Qiaodan Deng, Cuicui Liu, Jiahui Xu, Rui Zhang, Quentin Liu, Guo-Hong Hu, Chong Liu, Yi-Zhou Jiang, Zhi-Ming Shao, Ceshi Chen, Suling Liu
IL1R2 blockade alleviates immunosuppression and potentiates anti-PD-1 efficacy in triple-negative breast cancer. Cancer research (2024)
Yuwei Li, Yuzheng Xu, Caijin Lin, Xi Jin, Ding Ma, Zhi-Ming Shao
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer biology & medicine 21 (5) (2024)
Yuwei Li, Yuzheng Xu, Caijin Lin, Xi Jin, Ding Ma, Zhi-Ming Shao
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer biology & medicine 21 (5) (2024)
Yuwei Li, Yuzheng Xu, Caijin Lin, Xi Jin, Ding Ma, Zhi-Ming Shao
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer biology & medicine 21 (5) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Yuwei Li, Yuzheng Xu, Caijin Lin, Xi Jin, Ding Ma, Zhi-Ming Shao
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer biology & medicine (2024)
Li-Ping Ge, Xi Jin, Ding Ma, Zi-Yu Wang, Cheng-Lin Liu, Chao-Zheng Zhou, Shen Zhao, Tian-Jian Yu, Xi-Yu Liu, Gen-Hong Di, Zhi-Ming Shao, Yi-Zhou Jiang
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell research 34 (1) (2024)
Min-Ying Huang, Shu-Yuan Hu, Jia Dong, Ling Deng, Lisa Andriani, Xiao-Yan Ma, Yin-Ling Zhang, Fang-Lin Zhang, Zhi-Ming Shao, Da-Qiang Li
The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer. Cancer research 84 (16) (2024)
Liang Huang, Da Pang, Hongjian Yang, Wei Li, Shusen Wang, Shude Cui, Ning Liao, Yongsheng Wang, Chuan Wang, Yuan-Ching Chang, Hwei-Chung Wang, Seok Yun Kang, Jae Hong Seo, Kunwei Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Haiyan Wang, François Lamour, Grace Song, Michelle Curran, Chunzhe Duan, Sanne Lysbet de Haas, Eleonora Restuccia, Zhi-Ming Shao
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nature communications 15 (1) (2024)
Yi-Zhou Jiang, Ding Ma, Xi Jin, Yi Xiao, Ying Yu, Jinxiu Shi, Yi-Fan Zhou, Tong Fu, Cai-Jin Lin, Lei-Jie Dai, Cheng-Lin Liu, Shen Zhao, Guan-Hua Su, Wanwan Hou, Ya-Qing Liu, Qing-Wang Chen, Jingcheng Yang, Naixin Zhang, Wen-Juan Zhang, Wei Liu, Weigang Ge, Wen-Tao Yang, Chao You, Yajia Gu, Virginia Kaklamani, François Bertucci, Claire Verschraegen, Anneleen Daemen, Nakul M Shah, Ting Wang, Tiannan Guo, Le-Ming Shi, Charles M Perou, Yuanting Zheng, Wei Huang, Zhi-Ming Shao
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nature cancer (2024)
Liang Huang, Da Pang, Hongjian Yang, Wei Li, Shusen Wang, Shude Cui, Ning Liao, Yongsheng Wang, Chuan Wang, Yuan-Ching Chang, Hwei-Chung Wang, Seok Yun Kang, Jae Hong Seo, Kunwei Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Haiyan Wang, François Lamour, Grace Song, Michelle Curran, Chunzhe Duan, Sanne Lysbet de Haas, Eleonora Restuccia, Zhi-Ming Shao
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nature communications 15 (1) (2024)
Wen-Ting Peng, Xi Jin, Xiao-En Xu, Yun-Song Yang, Ding Ma, Zhi-Ming Shao, Yi-Zhou Jiang
Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer. Cancer research (2023)
Cai-Jin Lin, Wen-Xuan Xiao, Tong Fu, Xi Jin, Zhi-Ming Shao, Gen-Hong Di
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies. NPJ breast cancer 9 (1) (2023)
Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, A-Yong Cao, Jun-Jie Li, Ke-Da Yu, Guang-Yu Liu, Jiong Wu, Tao Sun, Jiu-Wei Cui, Zheng Lv, Hui-Ping Li, Xiao-Yu Zhu, Yi-Zhou Jiang, Zhong-Hua Wang, Zhi-Ming Shao
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell research (2023)
Fei-Lin Qu, Jun-Jie Li, Zhi-Ming Shao
Comments on: a prediction model for distant metastasis after isolated locoregional recurrence of breast cancer. Breast cancer research and treatment (2023)
Xi Jin, Yi-Fan Zhou, Ding Ma, Shen Zhao, Cai-Jin Lin, Yi Xiao, Tong Fu, Cheng-Lin Liu, Yi-Yu Chen, Wen-Xuan Xiao, Ya-Qing Liu, Qing-Wang Chen, Ying Yu, Le-Ming Shi, Jin-Xiu Shi, Wei Huang, John F R Robertson, Yi-Zhou Jiang, Zhi-Ming Shao
Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nature genetics (2023)
Guan-Hua Su, Yi Xiao, Chao You, Ren-Cheng Zheng, Shen Zhao, Shi-Yun Sun, Jia-Yin Zhou, Lu-Yi Lin, He Wang, Zhi-Ming Shao, Ya-Jia Gu, Yi-Zhou Jiang
Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets. Science advances 9 (40) (2023)
Fei-Lin Qu, Song-Yang Wu, Jun-Jie Li, Zhi-Ming Shao
Ipsilateral breast tumor recurrence after breast-conserving surgery: insights into biology and treatment. Breast cancer research and treatment (2023)
Lei-Jie Dai, Ding Ma, Yu-Zheng Xu, Ming Li, Yu-Wei Li, Yi Xiao, Xi Jin, Song-Yang Wu, Ya-Xin Zhao, Han Wang, Wen-Tao Yang, Yi-Zhou Jiang, Zhi-Ming Shao
Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer. Nature communications 14 (1) (2023)
Shen Zhao, De-Pin Chen, Tong Fu, Jing-Cheng Yang, Ding Ma, Xiu-Zhi Zhu, Xiang-Xue Wang, Yi-Ping Jiao, Xi Jin, Yi Xiao, Wen-Xuan Xiao, Hu-Yunlong Zhang, Hong Lv, Anant Madabhushi, Wen-Tao Yang, Yi-Zhou Jiang, Jun Xu, Zhi-Ming Shao
Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer. Nature communications 14 (1) (2023)
Wen-Ting Peng, Xi Jin, Xiao-En Xu, Yun-Song Yang, Ding Ma, Zhi-Ming Shao, Yi-Zhou Jiang
Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer. Cancer research 83 (10) (2023)
Junjie Li, Li Chen, Wei Tan, Fang Qi, Yang Zhang, Zhonghua Wang, Zhi-Ming Shao
Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis. Cancer biology & medicine (2022)
Fei-Lin Qu, Cai-Jin Lin, Zhe-Bin Liu, A-Yong Cao, Jiong Wu, Guang-Yu Liu, Ke-Da Yu, Gen-Hong Di, Jun-Jie Li, Zhi-Ming Shao
Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe? Breast cancer research and treatment 196 (1) (2022)
Ding Ma, Si-Yu Chen, Jin-Xiao Ren, Yu-Chen Pei, Cong-Wei Jiang, Shen Zhao, Yi Xiao, Xiao-En Xu, Guang-Yu Liu, Xin Hu, Xiao-Zhen Liang, Ke-Da Yu, Da-Qiang Li, Yi-Zhou Jiang, Zhi-Ming Shao
Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. Journal of the National Cancer Institute 113 (7) (2022)
Yin Liu, Lei Fan, Zhong-Hua Wang, Zhi-Ming Shao
Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study. The oncologist (2022)
Fei-Lin Qu, Jun-Jie Li, Zhi-Ming Shao
Comments on: The clinical relevance of various methods of classifying ipsilateral breast tumor recurrence as either true local recurrence or new primary. Breast cancer research and treatment (2022)
Li Liao, Yin-Ling Zhang, Ling Deng, Chao Chen, Xiao-Yan Ma, Lisa Andriani, Shao-Ying Yang, Shu-Yuan Hu, Fang-Lin Zhang, Zhi-Ming Shao, Da-Qiang Li
Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer. Cancer research (2022)
Rui Ding, Yi Xiao, Miao Mo, Ying Zheng, Yi-Zhou Jiang, Zhi-Ming Shao
Breast cancer screening and early diagnosis in Chinese women. Cancer biology & medicine (2022)
Yi-Zhou Jiang, Li-Ping Ge, Xi Jin, Lei Fan, Min He, Yin Liu, Li Chen, Wen-Jia Zuo, Jiong Wu, Guang-Yu Liu, Gen-Hong Di, Zhong-Hua Wang, Ke-Da Yu, Zhi-Ming Shao
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations. Breast cancer research and treatment 185 (2) (2020)
Shen Zhao, Ding Ma, Yi Xiao, Xiao-Mei Li, Jian-Li Ma, Han Zhang, Xiao-Li Xu, Hong Lv, Wen-Hua Jiang, Wen-Tao Yang, Yi-Zhou Jiang, Qing-Yuan Zhang, Zhi-Ming Shao
Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. The oncologist 25 (10) (2020)
Ding Ma, Yi-Zhou Jiang, Yi Xiao, Meng-Dan Xie, Shen Zhao, Xi Jin, Xiao-En Xu, Zhi-Ming Shao
Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies. Cancer 126 (14) (2020)
Guangdong Xie, Haiyuan Yang, Ding Ma, Yihua Sun, Haiquan Chen, Xin Hu, Yi-Zhou Jiang, Zhi-Ming Shao
Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer. International journal of cancer 145 (10) (2019)

Zhi-Ming Shao.css-eqlu8i{font-size:small;padding-left:4px;} (Zhiming Shao, Zhimin Shao)

Publication Activity (10 Years)

Top Topics

Top Venues

Zhi-Ming Shao (Zhiming Shao, Zhimin Shao)